Substance
PEMBROLIZUMAB
Global reference: every product and company linked to this substance.
- cas: 1374853-91-4
- ncit: C106432
- rxnorm: 1547545
- unii: DPT0O3T46P
KEYLYNK-010 COMPONENT PEMBROLIZUMAB · KEYTRUDA · KEYTRUDA QLEX COMPONENT PEMBROLIZUMAB · MK-3475 · pembrolizumab [INN] · PEMBROLIZUMAB [JAN] · PEMBROLIZUMAB [USAN] · Pembrolizumab [WHO-DD] · SCH-900475
Revenue by product (3)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| MERCK & COMPANY INC. COMMON STOCK (NEW) | KEYTRUDA | Q2 2026 | $7.9B |
| MERCK & COMPANY INC. COMMON STOCK (NEW) | KEYTRUDA | Q2 2026 | $7.9B |
| MERCK & COMPANY INC. COMMON STOCK (NEW) | KEYTRUDA QLEX | Q2 2026 | $463.0M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (3)
- KEYTRUDA · MERCK & COMPANY INC. COMMON STOCK (NEW)
- KEYTRUDA QLEX · MERCK & COMPANY INC. COMMON STOCK (NEW)
- KEYTRUDA · MERCK & COMPANY INC. COMMON STOCK (NEW)